Outlook Therapeutics Inc’s filing revealed that its Director Haddadin Yezan Munther acquired Company’s shares for reported $22242.0 on Mar 28 ’24. In the deal valued at $11.82 per share,1,882 shares were bought. As a result of this transaction, Haddadin Yezan Munther now holds 5,049 shares worth roughly $46753.74.
Then, Evanson Jeff bought 62,484 shares, generating $26,243 in total proceeds. Upon buying the shares at $0.42, the CHIEF COMMERCIAL OFFICER now owns 808,459 shares.
Before that, Dagnon Terry sold 520,000 shares. Outlook Therapeutics Inc shares valued at $590,200 were divested by the Chief Operations Officer at a price of $1.14 per share. As a result of the transaction, Dagnon Terry now holds 653,058 shares, worth roughly $6.05 million.
BTIG Research upgraded its Outlook Therapeutics Inc [OTLK] rating to a Buy from a a Neutral in a research note published recently. A number of analysts have revised their coverage, including Chardan Capital Markets’s analysts, who increased its forecast for the stock in mid February from “a Neutral” to “a Buy”. Guggenheim also remained covering OTLK and has increased its forecast on January 25, 2024 with a “Buy” recommendation from previously “Neutral” rating. CapitalOne revised its rating on December 27, 2023. It rated OTLK as “an Overweight” which previously was an “an Equal weight”.
Price Performance Review of OTLK
On Tuesday, Outlook Therapeutics Inc [NASDAQ:OTLK] saw its stock fall -0.96% to $9.26. Over the last five days, the stock has lost -4.54%. Outlook Therapeutics Inc shares have risen nearly 17.51% since the year began. Nevertheless, the stocks have fallen -55.05% over the past one year. While a 52-week high of $40.60 was reached on 04/01/24, a 52-week low of $4.00 was recorded on 03/14/24. SMA at 50 days reached $8.40, while 200 days put it at $13.43. A total of 0.36 million shares were traded, compared to the trading of 0.9 million shares in the previous session.
Levels Of Support And Resistance For OTLK Stock
The 24-hour chart illustrates a support level at 8.87, which if violated will result in even more drops to 8.47. On the upside, there is a resistance level at 9.82. A further resistance level may holdings at 10.37. The Relative Strength Index (RSI) on the 14-day chart is 53.11, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 0.19, which suggests price will go down in the next trading period. Percent R suggests that price movement has been low at 58.76%. Stochastics %K at 41.74% indicates the stock is a holding.
How much short interest is there in Outlook Therapeutics Inc?
A steep rise in short interest was recorded in Outlook Therapeutics Inc stocks on Mar 15, 2024, growing by 0.13 million shares to a total of 0.79 million shares. Yahoo Finance data shows the prior-month short interest on Feb 15, 2024 was 0.66 million shares. There was a rise of 15.97%, which implies that there is a positive sentiment for the stock. In spite of short shares comprising just 8.48% of the overall stock float, the days-to-cover ratio (short ratio) rose to 3.66.
